Vol. 46 | No. 2 | July-December 2018Back

Open Access

Effects of HER2 Receptor Antagonist (Trastuzumab And Lapatinib) on Cardiac Chamber Size and Function Measured by Echocardiography Among Early HER2 Positive Breast Cancer Patients in a Tertiary Hospital

Paul John L. Ablaza, Cresmelita M. Banez, Julie Ann Tapispisan
Dec 2018 DOI 10.69944/pjc.1600d61af9

More Info

Paul John L. Ablaza, MD; Cresmelita M. Banez, MD; Julie Ann Tapispisan, MD

Sto. Tomas University Hospital, University of Sto. Tomas, Manila

References
  1. D. Cardinale, A. Colombo, R. Torrisi, et al. Trastuzumab induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28, 3910–3916.
  2. D. Bovelli, G. Plataniotis & F. Roila. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of Oncology 21 (Supplement 5): v277–v282, 2010.
  3. Douraid K. Shakira, Kakil I Rasul. Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management. J Clin Med Res 2009;1(1):8-12.
  4. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008 Jun;83(6):679-86.
  5. Sendur MA, Aksoy S, Altundag K. Cardiotoxicity of novel HER2- targeted therapies. Curr Med Res Opin. 2013 Aug;29(8):1015-24.
  6. Banchs J, Jefferies JL, Plana JC, et al. Imaging for cardiotoxicity in cancer patients. Tex Heart Inst J 2011;38:268-9.l
  7. Noam F Pondé,1 Matteo Lambertini,1,2 and Evandro de Azambuja. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 2016;1:e000073.
  8. Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012;13:135–44.
  9. Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1183–92.
  10. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet Lond Engl 2012;379:633–40.
  11. Valachis A, Nearchou A, Polyzos NP et al. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer 2013;133:2245–52.
  12. Spector NL, Yarden Y, Smith B, et al. Activation of AMP activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci2007;DOI:10.1073/pnas.0701286104.
  13. Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: a ‘dual-hit’. Exp Clin Cardiol. 2011;16(3):70-74.
  14. Sandoo A, Kitas GD, Carmichael AR. Breast cancer therapy and cardiovascular risk: focus on trastuzumab. Vasc Health Risk Manag. 2015;11:223-228.
  15. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol. 2010;28(25):3901-3904.
  16. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021-1028.
  17. Earl HM, Vallier A-L, Dunn J, et al. Trastuzumab-associated cardiac events in the Persephone trial. Br J Cancer. 2016;115(12):1462-1470.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.